ANCA-associated vasculitis (AAV) patients with antibodies targeting the myeloperoxidase (MPO) protein have higher levels of immune-activating pieces of the…
Articles by Marisa Wexler, MS
People with active granulomatosis with polyangiitis (GPA), the most common type of ANCA-associated vasculitis (AAV), had significantly higher levels…
Amgen said it declined a U.S. Food and Drug Administration (FDA) request to voluntarily withdraw Tavneos (avacopan), an…
Following questions about the integrity of clinical trial data, regulators in Europe are taking a second look at Tavneos…
A study linked high levels of a blood protein called CXCL6 with lung disease in people with ANCA-associated vasculitis…
The U.S. Patent and Trademark Office (USPTO) has granted Conduit Pharmaceuticals a patent for AZD1656, its experimental therapy for…
Disease symptoms among people with ANCA-associated vasculitis (AAV) were found to vary by age at diagnosis and biological sex,…
The likelihood of disease recurrence in people with anti-neutrophilic cytoplasmic autoantibody (ANCA)-associated vasculitis (AAV) varies by disease type, with those…
Lixudebart (ALE.F02), an experimental therapy Alentis Therapeutics is developing to help preserve kidney health in ANCA-associated vasculitis (AAV),…
Self-reactive antibodies, or autoantibodies, against two proteins — homeostatic iron regulator, or HFE, and synaptotagmin 5, known as SYT5 —…